ID   CASP9_HUMAN             Reviewed;         416 AA.
AC   P55211; B4E1A3; O95348; Q53Y70; Q5JRU9; Q5UGI1; Q92852; Q9BQ62; Q9UEQ3;
AC   Q9UIJ8;
DT   01-OCT-1996, integrated into UniProtKB/Swiss-Prot.
DT   22-FEB-2003, sequence version 3.
DT   18-JUN-2025, entry version 248.
DE   RecName: Full=Caspase-9;
DE            Short=CASP-9;
DE            EC=3.4.22.62 {ECO:0000269|PubMed:16916640, ECO:0000269|PubMed:23516580, ECO:0000269|PubMed:27889207};
DE   AltName: Full=Apoptotic protease Mch-6;
DE   AltName: Full=Apoptotic protease-activating factor 3;
DE            Short=APAF-3;
DE   AltName: Full=ICE-like apoptotic protease 6;
DE            Short=ICE-LAP6;
DE   Contains:
DE     RecName: Full=Caspase-9 subunit p35;
DE   Contains:
DE     RecName: Full=Caspase-9 subunit p10;
DE   Flags: Precursor;
GN   Name=CASP9; Synonyms=MCH6;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS VAL-28 AND ARG-221.
RX   PubMed=8663294; DOI=10.1074/jbc.271.28.16720;
RA   Duan H., Orth K., Chinnaiyan A.M., Poirier G.G., Froelich C.J., He W.-W.,
RA   Dixit V.M.;
RT   "ICE-LAP6, a novel member of the ICE/Ced-3 gene family, is activated by the
RT   cytotoxic T cell protease granzyme B.";
RL   J. Biol. Chem. 271:16720-16724(1996).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND PROTEOLYTIC PROCESSING.
RC   TISSUE=T-cell;
RX   PubMed=8900201; DOI=10.1074/jbc.271.43.27099;
RA   Srinivasula S.M., Fernandes-Alnemri T., Zangrilli J., Robertson N.,
RA   Armstrong R.C., Wang L., Trapani J.A., Tomaselli K.J., Litwack G.,
RA   Alnemri E.S.;
RT   "The Ced-3/interleukin 1beta converting enzyme-like homolog Mch6 and the
RT   lamin-cleaving enzyme Mch2alpha are substrates for the apoptotic mediator
RT   CPP32.";
RL   J. Biol. Chem. 271:27099-27106(1996).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=10384055; DOI=10.1007/s003359901086;
RA   Hadano S., Nasir J., Nichol K., Rasper D.M., Vaillancourt J.P.,
RA   Sherer S.W., Beatty B.G., Ikeda J.E., Nicholson D.W., Hayden M.R.;
RT   "Genomic organization of the human caspase-9 gene on chromosome 1p36.1-
RT   p36.3.";
RL   Mamm. Genome 10:757-760(1999).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND FUNCTION (ISOFORM 2).
RX   PubMed=10070954;
RA   Srinivasula S.M., Ahmad M., Guo Y., Zhan Y., Lazebnik Y.,
RA   Fernandes-Alnemri T., Alnemri E.S.;
RT   "Identification of an endogenous dominant-negative short isoform of
RT   caspase-9 that can regulate apoptosis.";
RL   Cancer Res. 59:999-1002(1999).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Stomach cancer;
RA   Izawa M., Mori T., Ito H., Sairenji T.;
RT   "Molecular cloning and sequencing of a cDNA predicting an alternative form
RT   of pro-caspase-9 from human gastric cancer cell lines.";
RL   Submitted (JUN-1998) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Miho Y., Momoi T., Fujita E.;
RT   "A novel splicing product of human caspase-9 lacking protease activity.";
RL   Submitted (DEC-1998) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANT VAL-28.
RX   PubMed=9890966; DOI=10.1074/jbc.274.4.2072;
RA   Seol D.W., Billiar T.R.;
RT   "A caspase-9 variant missing the catalytic site is an endogenous inhibitor
RT   of apoptosis.";
RL   J. Biol. Chem. 274:2072-2076(1999).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), AND VARIANT VAL-28.
RX   PubMed=16780893; DOI=10.1016/j.lfs.2006.04.026;
RA   Wang P., Shi T., Ma D.;
RT   "Cloning of a novel human caspase-9 splice variant containing only the CARD
RT   domain.";
RL   Life Sci. 79:934-940(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS VAL-28; LEU-99; ILE-102;
RP   VAL-106; ASP-114; HIS-173 AND ARG-221.
RG   NIEHS SNPs program;
RL   Submitted (JAN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 4).
RC   TISSUE=Kidney;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [12]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D., Dunham A.,
RA   Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A., Jones M.C., Gillson C.,
RA   Searle S., Zhou Y., Kokocinski F., McDonald L., Evans R., Phillips K.,
RA   Atkinson A., Cooper R., Jones C., Hall R.E., Andrews T.D., Lloyd C.,
RA   Ainscough R., Almeida J.P., Ambrose K.D., Anderson F., Andrew R.W.,
RA   Ashwell R.I.S., Aubin K., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Beasley H., Bethel G., Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J.,
RA   Buckley D., Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y.,
RA   Clarke G., Clee C., Cobley V., Collier R.E., Corby N., Coville G.J.,
RA   Davies J., Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R., Hammond S.,
RA   Harrison E.S.I., Hart E., Haugen E., Heath P.D., Holmes S., Holt K.,
RA   Howden P.J., Hunt A.R., Hunt S.E., Hunter G., Isherwood J., James R.,
RA   Johnson C., Johnson D., Joy A., Kay M., Kershaw J.K., Kibukawa M.,
RA   Kimberley A.M., King A., Knights A.J., Lad H., Laird G., Lawlor S.,
RA   Leongamornlert D.A., Lloyd D.M., Loveland J., Lovell J., Lush M.J.,
RA   Lyne R., Martin S., Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W.,
RA   McLaren S., Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C., Subramanian S.,
RA   Sycamore N., Tracey A., Tromans A., Van Helmond Z., Wall M., Wallis J.M.,
RA   White S., Whitehead S.L., Wilkinson J.E., Willey D.L., Williams H.,
RA   Wilming L., Wray P.W., Wu Z., Coulson A., Vaudin M., Sulston J.E.,
RA   Durbin R.M., Hubbard T., Wooster R., Dunham I., Carter N.P., McVean G.,
RA   Ross M.T., Harrow J., Olson M.V., Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [13]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [14]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Eye, and Lymph;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [15]
RP   PHOSPHORYLATION AT THR-125.
RX   PubMed=12792650; DOI=10.1038/ncb1005;
RA   Allan L.A., Morrice N., Brady S., Magee G., Pathak S., Clarke P.R.;
RT   "Inhibition of caspase-9 through phosphorylation at Thr 125 by ERK MAPK.";
RL   Nat. Cell Biol. 5:647-654(2003).
RN   [16]
RP   INTERACTION WITH BIRC6/BRUCE.
RX   PubMed=15200957; DOI=10.1016/j.molcel.2004.05.018;
RA   Bartke T., Pohl C., Pyrowolakis G., Jentsch S.;
RT   "Dual role of BRUCE as an antiapoptotic IAP and a chimeric E2/E3 ubiquitin
RT   ligase.";
RL   Mol. Cell 14:801-811(2004).
RN   [17]
RP   FUNCTION IN APOPTOSIS, INTERACTION WITH ABL1, PROTEOLYTIC PROCESSING,
RP   PHOSPHORYLATION AT TYR-153 BY ABL1, AND MUTAGENESIS OF TYR-153.
RX   PubMed=15657060; DOI=10.1074/jbc.m413787200;
RA   Raina D., Pandey P., Ahmad R., Bharti A., Ren J., Kharbanda S.,
RA   Weichselbaum R., Kufe D.;
RT   "c-Abl tyrosine kinase regulates caspase-9 autocleavage in the apoptotic
RT   response to DNA damage.";
RL   J. Biol. Chem. 280:11147-11151(2005).
RN   [18]
RP   INTERACTION WITH HAX1, TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=16857965; DOI=10.1161/01.res.0000237387.05259.a5;
RA   Han Y., Chen Y.S., Liu Z., Bodyak N., Rigor D., Bisping E., Pu W.T.,
RA   Kang P.M.;
RT   "Overexpression of HAX-1 protects cardiac myocytes from apoptosis through
RT   caspase-9 inhibition.";
RL   Circ. Res. 99:415-423(2006).
RN   [19]
RP   FUNCTION.
RX   PubMed=16352606; DOI=10.1074/jbc.m507393200;
RA   Twiddy D., Cohen G.M., Macfarlane M., Cain K.;
RT   "Caspase-7 is directly activated by the approximately 700-kDa apoptosome
RT   complex and is released as a stable XIAP-caspase-7 approximately 200-kDa
RT   complex.";
RL   J. Biol. Chem. 281:3876-3888(2006).
RN   [20]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=16916640; DOI=10.1016/j.molcel.2006.06.020;
RA   Denault J.B., Bekes M., Scott F.L., Sexton K.M., Bogyo M., Salvesen G.S.;
RT   "Engineered hybrid dimers: tracking the activation pathway of caspase-7.";
RL   Mol. Cell 23:523-533(2006).
RN   [21]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-125; SER-302 AND SER-307, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [22]
RP   INTERACTION WITH BCL2L10.
RX   PubMed=19255499; DOI=10.1159/000204088;
RA   Kim J.H., Yoon S., Won M., Sim S.H., Ko J.J., Han S., Lee K.A., Lee K.,
RA   Bae J.;
RT   "HIP1R interacts with a member of Bcl-2 family, BCL2L10, and induces BAK-
RT   dependent cell death.";
RL   Cell. Physiol. Biochem. 23:43-52(2009).
RN   [23]
RP   INTERACTION WITH EFHD2.
RX   PubMed=19118655; DOI=10.1016/j.jprot.2008.11.016;
RA   Checinska A., Giaccone G., Rodriguez J.A., Kruyt F.A.E., Jimenez C.R.;
RT   "Comparative proteomics analysis of caspase-9-protein complexes in
RT   untreated and cytochrome c/dATP stimulated lysates of NSCLC cells.";
RL   J. Proteomics 72:575-585(2009).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-307, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-310, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=27889207; DOI=10.1016/j.str.2016.11.001;
RA   Eron S.J., Raghupathi K., Hardy J.A.;
RT   "Dual site phosphorylation of caspase-7 by PAK2 blocks apoptotic activity
RT   by two distinct mechanisms.";
RL   Structure 25:27-39(2017).
RN   [27]
RP   FUNCTION, ADP-RIBOXANATION AT ARG-355 (MICROBIAL INFECTION), AND
RP   MUTAGENESIS OF ARG-355.
RX   PubMed=35446120; DOI=10.1128/mbio.00690-22;
RA   Liu Y., Zeng H., Hou Y., Li Z., Li L., Song X., Ding J., Shao F., Xu Y.;
RT   "Calmodulin binding activates chromobacterium CopC effector to ADP-
RT   riboxanate host apoptotic caspases.";
RL   MBio 0:0-0(2022).
RN   [28]
RP   FUNCTION, AND ADP-RIBOXANATION AT ARG-355 (MICROBIAL INFECTION).
RX   PubMed=35338844; DOI=10.1016/j.molcel.2022.03.010;
RA   Peng T., Tao X., Xia Z., Hu S., Xue J., Zhu Q., Pan X., Zhang Q., Li S.;
RT   "Pathogen hijacks programmed cell death signaling by arginine ADPR-
RT   deacylization of caspases.";
RL   Mol. Cell 82:1806-1820(2022).
RN   [29]
RP   FUNCTION, ACTIVITY REGULATION, AND UBIQUITINATION BY BIRC6.
RX   PubMed=36758106; DOI=10.1126/science.ade8840;
RA   Dietz L., Ellison C.J., Riechmann C., Cassidy C.K., Felfoldi F.D.,
RA   Pinto-Fernandez A., Kessler B.M., Elliott P.R.;
RT   "Structural basis for SMAC-mediated antagonism of caspase inhibition by the
RT   giant ubiquitin ligase BIRC6.";
RL   Science 379:1112-1117(2023).
RN   [30]
RP   FUNCTION, ACTIVITY REGULATION, AND UBIQUITINATION BY BIRC6.
RX   PubMed=36758105; DOI=10.1126/science.ade8873;
RA   Ehrmann J.F., Grabarczyk D.B., Heinke M., Deszcz L., Kurzbauer R.,
RA   Hudecz O., Shulkina A., Gogova R., Meinhart A., Versteeg G.A., Clausen T.;
RT   "Structural basis for regulation of apoptosis and autophagy by the
RT   BIRC6/SMAC complex.";
RL   Science 379:1117-1123(2023).
RN   [31]
RP   X-RAY CRYSTALLOGRAPHY (2.8 ANGSTROMS) OF 140-416, AND SUBUNIT.
RX   PubMed=11734640; DOI=10.1073/pnas.231465798;
RA   Renatus M., Stennicke H.R., Scott F.L., Liddington R.C., Salvesen G.S.;
RT   "Dimer formation drives the activation of the cell death protease caspase
RT   9.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:14250-14255(2001).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 140-416 IN COMPLEX WITH
RP   BIRC4/XIAP.
RX   PubMed=12620238; DOI=10.1016/s1097-2765(03)00054-6;
RA   Shiozaki E.N., Chai J., Rigotti D.J., Riedl S.J., Li P., Srinivasula S.M.,
RA   Alnemri E.S., Fairman R., Shi Y.;
RT   "Mechanism of XIAP-mediated inhibition of caspase-9.";
RL   Mol. Cell 11:519-527(2003).
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (3.49 ANGSTROMS) OF 140-416 IN COMPLEX WITH E.COLI
RP   NLEF, INTERACTION WITH E.COLI NLEF, SUBUNIT, CATALYTIC ACTIVITY, FUNCTION,
RP   AND ACTIVITY REGULATION.
RX   PubMed=23516580; DOI=10.1371/journal.pone.0058937;
RA   Blasche S., Mortl M., Steuber H., Siszler G., Nisa S., Schwarz F.,
RA   Lavrik I., Gronewold T.M., Maskos K., Donnenberg M.S., Ullmann D., Uetz P.,
RA   Kogl M.;
RT   "The E. coli effector protein NleF is a caspase inhibitor.";
RL   PLoS ONE 8:E58937-E58937(2013).
CC   -!- FUNCTION: Involved in the activation cascade of caspases responsible
CC       for apoptosis execution. Binding of caspase-9 to Apaf-1 leads to
CC       activation of the protease which then cleaves and activates effector
CC       caspases caspase-3 (CASP3) or caspase-7 (CASP7). Promotes DNA damage-
CC       induced apoptosis in a ABL1/c-Abl-dependent manner. Proteolytically
CC       cleaves poly(ADP-ribose) polymerase (PARP). Cleaves BIRC6 following
CC       inhibition of BIRC6-caspase binding by DIABLO/SMAC (PubMed:36758105,
CC       PubMed:36758106). {ECO:0000269|PubMed:15657060,
CC       ECO:0000269|PubMed:16352606, ECO:0000269|PubMed:16916640,
CC       ECO:0000269|PubMed:23516580, ECO:0000269|PubMed:27889207,
CC       ECO:0000269|PubMed:35338844, ECO:0000269|PubMed:35446120}.
CC   -!- FUNCTION: [Isoform 2]: Lacks activity is an dominant-negative inhibitor
CC       of caspase-9. {ECO:0000269|PubMed:10070954}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=Strict requirement for an Asp residue at position P1 and with
CC         a marked preference for His at position P2. It has a preferred
CC         cleavage sequence of Leu-Gly-His-Asp-|-Xaa.; EC=3.4.22.62;
CC         Evidence={ECO:0000269|PubMed:16916640, ECO:0000269|PubMed:23516580,
CC         ECO:0000269|PubMed:27889207};
CC   -!- ACTIVITY REGULATION: Inhibited by the effector protein NleF that is
CC       produced by pathogenic E.coli; this inhibits apoptosis
CC       (PubMed:23516580). Inhibited by BIRC6; following inhibition of BIRC6-
CC       caspase binding by DIABLO/SMAC, BIRC6 is subjected to caspase cleavage,
CC       leading to an increase in active caspases (PubMed:36758105,
CC       PubMed:36758106). {ECO:0000269|PubMed:23516580,
CC       ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106}.
CC   -!- SUBUNIT: Heterotetramer that consists of two anti-parallel arranged
CC       heterodimers, each one formed by a 35 kDa (p35) and a 10 kDa (p10)
CC       subunit. Caspase-9 and APAF1 bind to each other via their respective
CC       NH2-terminal CED-3 homologous domains in the presence of cytochrome C
CC       and ATP. Interacts (inactive form) with EFHD2. Interacts with HAX1.
CC       Interacts with BIRC2/c-IAP1, XIAP/BIRC4, BIRC5/survivin, BIRC6/bruce
CC       and BIRC7/livin. Interacts with ABL1 (via SH3 domain); the interaction
CC       is direct and increases in the response of cells to genotoxic stress
CC       and ABL1/c-Abl activation. Interacts with BCL2L10 (PubMed:19255499).
CC       Interacts with NleF from pathogenic E.coli.
CC       {ECO:0000269|PubMed:11734640, ECO:0000269|PubMed:12620238,
CC       ECO:0000269|PubMed:15200957, ECO:0000269|PubMed:15657060,
CC       ECO:0000269|PubMed:16857965, ECO:0000269|PubMed:19118655,
CC       ECO:0000269|PubMed:19255499, ECO:0000269|PubMed:23516580}.
CC   -!- INTERACTION:
CC       P55211; O14727: APAF1; NbExp=22; IntAct=EBI-516799, EBI-446492;
CC       P55211; Q13490: BIRC2; NbExp=12; IntAct=EBI-516799, EBI-514538;
CC       P55211; Q96CA5: BIRC7; NbExp=12; IntAct=EBI-516799, EBI-517623;
CC       P55211; Q6PIA0: BIRC8; NbExp=3; IntAct=EBI-516799, EBI-2129837;
CC       P55211; P42574: CASP3; NbExp=2; IntAct=EBI-516799, EBI-524064;
CC       P55211; P43146: DCC; NbExp=2; IntAct=EBI-516799, EBI-1222919;
CC       P55211; Q13418: ILK; NbExp=2; IntAct=EBI-516799, EBI-747644;
CC       P55211; P98170: XIAP; NbExp=23; IntAct=EBI-516799, EBI-517127;
CC       P55211; Q8XAL7: nleF; Xeno; NbExp=6; IntAct=EBI-516799, EBI-10039292;
CC       P55211-1; P55211-1: CASP9; NbExp=3; IntAct=EBI-15553290, EBI-15553290;
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1; Synonyms=9L, Alpha;
CC         IsoId=P55211-1; Sequence=Displayed;
CC       Name=2; Synonyms=9S, Beta;
CC         IsoId=P55211-2; Sequence=VSP_000818;
CC       Name=3; Synonyms=Gamma;
CC         IsoId=P55211-3; Sequence=VSP_043910, VSP_043911;
CC       Name=4;
CC         IsoId=P55211-4; Sequence=VSP_044256;
CC   -!- TISSUE SPECIFICITY: Ubiquitous, with highest expression in the heart,
CC       moderate expression in liver, skeletal muscle, and pancreas. Low levels
CC       in all other tissues. Within the heart, specifically expressed in
CC       myocytes. {ECO:0000269|PubMed:16857965}.
CC   -!- DEVELOPMENTAL STAGE: Expressed at low levels in fetal heart, at
CC       moderate levels in neonate heart, and at high levels in adult heart.
CC       {ECO:0000269|PubMed:16857965}.
CC   -!- PTM: Cleavages at Asp-315 by granzyme B and at Asp-330 by caspase-3
CC       generate the two active subunits. Caspase-8 and -10 can also be
CC       involved in these processing events.
CC   -!- PTM: Phosphorylated at Thr-125 by MAPK1/ERK2. Phosphorylation at Thr-
CC       125 is sufficient to block caspase-9 processing and subsequent caspase-
CC       3 activation. Phosphorylation on Tyr-153 by ABL1/c-Abl; occurs in the
CC       response of cells to DNA damage. {ECO:0000269|PubMed:12792650,
CC       ECO:0000269|PubMed:15657060}.
CC   -!- PTM: (Microbial infection) ADP-riboxanation by C.violaceum CopC blocks
CC       CASP9 processing, preventing CASP9 activation and ability to mediate
CC       intrinsic apoptosis. {ECO:0000269|PubMed:35338844,
CC       ECO:0000269|PubMed:35446120}.
CC   -!- PTM: Ubiquitinated by BIRC6; this activity is inhibited by DIABLO/SMAC.
CC       {ECO:0000269|PubMed:36758105, ECO:0000269|PubMed:36758106}.
CC   -!- MISCELLANEOUS: [Isoform 3]: May function as an endogenous apoptotic
CC       inhibitor, inhibits the BAX-mediated cleavage of procaspase-3.
CC       {ECO:0000305}.
CC   -!- SIMILARITY: Belongs to the peptidase C14A family. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="https://atlasgeneticsoncology.org/gene/423/CASP9";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=Caspase-9 entry;
CC       URL="https://en.wikipedia.org/wiki/Caspase-9";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U56390; AAC50640.1; -; mRNA.
DR   EMBL; U60521; AAC50776.1; -; mRNA.
DR   EMBL; AB019205; BAA82697.1; -; Genomic_DNA.
DR   EMBL; AF093130; AAD12248.1; -; mRNA.
DR   EMBL; AB015653; BAA78780.1; -; mRNA.
DR   EMBL; AB020979; BAA87905.1; -; mRNA.
DR   EMBL; AF110376; AAD13615.1; -; mRNA.
DR   EMBL; AY732490; AAV33129.1; -; mRNA.
DR   EMBL; AY214168; AAO21133.1; -; Genomic_DNA.
DR   EMBL; BT006911; AAP35557.1; -; mRNA.
DR   EMBL; AK303743; BAG64715.1; -; mRNA.
DR   EMBL; AL512883; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471167; EAW51730.1; -; Genomic_DNA.
DR   EMBL; CH471167; EAW51731.1; -; Genomic_DNA.
DR   EMBL; BC002452; AAH02452.1; -; mRNA.
DR   EMBL; BC006463; AAH06463.1; -; mRNA.
DR   CCDS; CCDS158.1; -. [P55211-1]
DR   CCDS; CCDS159.2; -. [P55211-4]
DR   CCDS; CCDS59995.1; -. [P55211-2]
DR   PIR; G02635; G02635.
DR   RefSeq; NP_001220.2; NM_001229.4. [P55211-1]
DR   RefSeq; NP_001264983.1; NM_001278054.2. [P55211-2]
DR   RefSeq; NP_127463.2; NM_032996.3. [P55211-4]
DR   RefSeq; XP_005246071.1; XM_005246014.3. [P55211-4]
DR   RefSeq; XP_054195099.1; XM_054339124.1. [P55211-4]
DR   PDB; 1JXQ; X-ray; 2.80 A; A/B/C/D=140-416.
DR   PDB; 1NW9; X-ray; 2.40 A; B=140-416.
DR   PDB; 2AR9; X-ray; 2.80 A; A/B/C/D=139-416.
DR   PDB; 3D9T; X-ray; 1.50 A; C/D=316-321.
DR   PDB; 3V3K; X-ray; 3.49 A; A/C/E/G/I/K/M/O=141-416.
DR   PDB; 3YGS; X-ray; 2.50 A; P=1-95.
DR   PDB; 4RHW; X-ray; 2.10 A; E/F=1-100.
DR   PDB; 5JUY; EM; 4.10 A; O/P/Q/R=1-95.
DR   PDB; 5WVC; X-ray; 2.99 A; B/D/F=1-128.
DR   PDB; 5WVE; EM; 4.40 A; S/T/U/V/Y=1-100.
DR   PDBsum; 1JXQ; -.
DR   PDBsum; 1NW9; -.
DR   PDBsum; 2AR9; -.
DR   PDBsum; 3D9T; -.
DR   PDBsum; 3V3K; -.
DR   PDBsum; 3YGS; -.
DR   PDBsum; 4RHW; -.
DR   PDBsum; 5JUY; -.
DR   PDBsum; 5WVC; -.
DR   PDBsum; 5WVE; -.
DR   AlphaFoldDB; P55211; -.
DR   EMDB; EMD-8178; -.
DR   SMR; P55211; -.
DR   BioGRID; 107292; 60.
DR   ComplexPortal; CPX-3762; Apoptosome.
DR   ComplexPortal; CPX-991; Caspase-9 complex.
DR   CORUM; P55211; -.
DR   DIP; DIP-27625N; -.
DR   ELM; P55211; -.
DR   FunCoup; P55211; 1767.
DR   IntAct; P55211; 31.
DR   MINT; P55211; -.
DR   STRING; 9606.ENSP00000330237; -.
DR   BindingDB; P55211; -.
DR   ChEMBL; CHEMBL2273; -.
DR   DrugBank; DB00282; Pamidronic acid.
DR   GuidetoPHARMACOLOGY; 1625; -.
DR   MEROPS; C14.010; -.
DR   TCDB; 8.A.217.1.1; the apoptosis cell death regulator (acdr) family.
DR   GlyGen; P55211; 2 sites, 1 O-linked glycan (1 site).
DR   iPTMnet; P55211; -.
DR   PhosphoSitePlus; P55211; -.
DR   BioMuta; CASP9; -.
DR   DMDM; 28558771; -.
DR   jPOST; P55211; -.
DR   MassIVE; P55211; -.
DR   PaxDb; 9606-ENSP00000330237; -.
DR   PeptideAtlas; P55211; -.
DR   ProteomicsDB; 56814; -. [P55211-1]
DR   ProteomicsDB; 56815; -. [P55211-2]
DR   ProteomicsDB; 56816; -. [P55211-3]
DR   ProteomicsDB; 5741; -.
DR   Pumba; P55211; -.
DR   Antibodypedia; 749; 1884 antibodies from 51 providers.
DR   DNASU; 842; -.
DR   Ensembl; ENST00000333868.10; ENSP00000330237.5; ENSG00000132906.18. [P55211-1]
DR   Ensembl; ENST00000348549.9; ENSP00000255256.7; ENSG00000132906.18. [P55211-2]
DR   Ensembl; ENST00000375890.8; ENSP00000365051.4; ENSG00000132906.18. [P55211-4]
DR   GeneID; 842; -.
DR   KEGG; hsa:842; -.
DR   MANE-Select; ENST00000333868.10; ENSP00000330237.5; NM_001229.5; NP_001220.2.
DR   UCSC; uc001awn.5; human. [P55211-1]
DR   AGR; HGNC:1511; -.
DR   CTD; 842; -.
DR   DisGeNET; 842; -.
DR   GeneCards; CASP9; -.
DR   HGNC; HGNC:1511; CASP9.
DR   HPA; ENSG00000132906; Low tissue specificity.
DR   MIM; 602234; gene.
DR   OpenTargets; ENSG00000132906; -.
DR   VEuPathDB; HostDB:ENSG00000132906; -.
DR   eggNOG; KOG3573; Eukaryota.
DR   GeneTree; ENSGT00940000159698; -.
DR   HOGENOM; CLU_036904_5_0_1; -.
DR   InParanoid; P55211; -.
DR   OMA; PFQEGPV; -.
DR   OrthoDB; 6044770at2759; -.
DR   PAN-GO; P55211; 6 GO annotations based on evolutionary models.
DR   PhylomeDB; P55211; -.
DR   BioCyc; MetaCyc:HS05705-MONOMER; -.
DR   BRENDA; 3.4.22.62; 2681.
DR   PathwayCommons; P55211; -.
DR   Reactome; R-HSA-111458; Formation of apoptosome.
DR   Reactome; R-HSA-111459; Activation of caspases through apoptosome-mediated cleavage.
DR   Reactome; R-HSA-111463; SMAC (DIABLO) binds to IAPs.
DR   Reactome; R-HSA-111464; SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes.
DR   Reactome; R-HSA-168638; NOD1/2 Signaling Pathway.
DR   Reactome; R-HSA-198323; AKT phosphorylates targets in the cytosol.
DR   Reactome; R-HSA-418889; Caspase activation via Dependence Receptors in the absence of ligand.
DR   Reactome; R-HSA-5674400; Constitutive Signaling by AKT1 E17K in Cancer.
DR   Reactome; R-HSA-9627069; Regulation of the apoptosome activity.
DR   SABIO-RK; P55211; -.
DR   SignaLink; P55211; -.
DR   SIGNOR; P55211; -.
DR   BioGRID-ORCS; 842; 16 hits in 1164 CRISPR screens.
DR   EvolutionaryTrace; P55211; -.
DR   GeneWiki; Caspase-9; -.
DR   GenomeRNAi; 842; -.
DR   Pharos; P55211; Tchem.
DR   PRO; PR:P55211; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   RNAct; P55211; protein.
DR   Bgee; ENSG00000132906; Expressed in adrenal tissue and 204 other cell types or tissues.
DR   ExpressionAtlas; P55211; baseline and differential.
DR   GO; GO:0043293; C:apoptosome; IDA:UniProtKB.
DR   GO; GO:0008303; C:caspase complex; IPI:ComplexPortal.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; IDA:UniProt.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0032991; C:protein-containing complex; IDA:UniProtKB.
DR   GO; GO:0004197; F:cysteine-type endopeptidase activity; IDA:UniProtKB.
DR   GO; GO:0008047; F:enzyme activator activity; TAS:ProtInc.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008233; F:peptidase activity; IDA:BHF-UCL.
DR   GO; GO:0019901; F:protein kinase binding; IDA:UniProtKB.
DR   GO; GO:0017124; F:SH3 domain binding; IDA:UniProtKB.
DR   GO; GO:0006915; P:apoptotic process; IMP:UniProtKB.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0034644; P:cellular response to UV; IDA:UniProtKB.
DR   GO; GO:0006974; P:DNA damage response; IDA:UniProtKB.
DR   GO; GO:1904019; P:epithelial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0044346; P:fibroblast apoptotic process; IEA:Ensembl.
DR   GO; GO:0034349; P:glial cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0097193; P:intrinsic apoptotic signaling pathway; IDA:UniProt.
DR   GO; GO:0008630; P:intrinsic apoptotic signaling pathway in response to DNA damage; IMP:UniProtKB.
DR   GO; GO:0001822; P:kidney development; IEA:Ensembl.
DR   GO; GO:0071887; P:leukocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0030220; P:platelet formation; TAS:UniProtKB.
DR   GO; GO:0043065; P:positive regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:1900119; P:positive regulation of execution phase of apoptosis; IDA:UniProt.
DR   GO; GO:0043525; P:positive regulation of neuron apoptotic process; IBA:GO_Central.
DR   GO; GO:0051604; P:protein maturation; IDA:UniProt.
DR   GO; GO:0016485; P:protein processing; IEA:Ensembl.
DR   GO; GO:0072347; P:response to anesthetic; IEA:Ensembl.
DR   GO; GO:0032025; P:response to cobalt ion; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0001666; P:response to hypoxia; IEA:Ensembl.
DR   GO; GO:0002931; P:response to ischemia; IEA:Ensembl.
DR   GO; GO:0032496; P:response to lipopolysaccharide; IEA:Ensembl.
DR   GO; GO:0042770; P:signal transduction in response to DNA damage; IDA:UniProtKB.
DR   CDD; cd08326; CARD_CASP9; 1.
DR   CDD; cd00032; CASc; 1.
DR   DisProt; DP02860; -.
DR   FunFam; 1.10.533.10:FF:000041; Caspase 9; 1.
DR   FunFam; 3.40.50.1460:FF:000012; Caspase 9; 1.
DR   Gene3D; 3.40.50.1460; -; 1.
DR   Gene3D; 1.10.533.10; Death Domain, Fas; 1.
DR   IDEAL; IID00718; -.
DR   InterPro; IPR001315; CARD.
DR   InterPro; IPR042147; CARD_CASP9.
DR   InterPro; IPR029030; Caspase-like_dom_sf.
DR   InterPro; IPR033139; Caspase_cys_AS.
DR   InterPro; IPR016129; Caspase_his_AS.
DR   InterPro; IPR011029; DEATH-like_dom_sf.
DR   InterPro; IPR002398; Pept_C14.
DR   InterPro; IPR011600; Pept_C14_caspase.
DR   InterPro; IPR002138; Pept_C14_p10.
DR   InterPro; IPR001309; Pept_C14_p20.
DR   InterPro; IPR015917; Pept_C14A.
DR   PANTHER; PTHR47901; CASPASE RECRUITMENT DOMAIN-CONTAINING PROTEIN 18; 1.
DR   PANTHER; PTHR47901:SF8; CASPASE-3; 1.
DR   Pfam; PF00619; CARD; 1.
DR   Pfam; PF00656; Peptidase_C14; 1.
DR   PIRSF; PIRSF038001; Caspase_ICE; 1.
DR   PRINTS; PR00376; IL1BCENZYME.
DR   SMART; SM00114; CARD; 1.
DR   SMART; SM00115; CASc; 1.
DR   SUPFAM; SSF52129; Caspase-like; 1.
DR   SUPFAM; SSF47986; DEATH domain; 1.
DR   PROSITE; PS50209; CARD; 1.
DR   PROSITE; PS01122; CASPASE_CYS; 1.
DR   PROSITE; PS01121; CASPASE_HIS; 1.
DR   PROSITE; PS50207; CASPASE_P10; 1.
DR   PROSITE; PS50208; CASPASE_P20; 1.
DR   neXtProt; NX_P55211; -.
DR   PharmGKB; PA26094; -.
DR   TreeFam; TF102023; -.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Apoptosis; Hydrolase; Phosphoprotein;
KW   Protease; Proteomics identification; Reference proteome; Thiol protease;
KW   Ubl conjugation; Zymogen.
FT   PROPEP          1..?
FT                   /evidence="ECO:0000255"
FT                   /id="PRO_0000004640"
FT   CHAIN           ?..315
FT                   /note="Caspase-9 subunit p35"
FT                   /id="PRO_0000004641"
FT   PROPEP          316..330
FT                   /id="PRO_0000004642"
FT   CHAIN           331..416
FT                   /note="Caspase-9 subunit p10"
FT                   /id="PRO_0000004643"
FT   DOMAIN          1..92
FT                   /note="CARD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00046"
FT   REGION          294..320
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   ACT_SITE        237
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        287
FT                   /evidence="ECO:0000250"
FT   MOD_RES         125
FT                   /note="Phosphothreonine; by MAPK1"
FT                   /evidence="ECO:0000269|PubMed:12792650,
FT                   ECO:0007744|PubMed:18669648"
FT   MOD_RES         153
FT                   /note="Phosphotyrosine; by ABL1"
FT                   /evidence="ECO:0000269|PubMed:15657060"
FT   MOD_RES         302
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         307
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:20068231"
FT   MOD_RES         310
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         355
FT                   /note="(Microbial infection) ADP-riboxanated arginine"
FT                   /evidence="ECO:0000269|PubMed:35338844,
FT                   ECO:0000269|PubMed:35446120"
FT   VAR_SEQ         1..83
FT                   /note="Missing (in isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_044256"
FT   VAR_SEQ         140..289
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:10070954,
FT                   ECO:0000303|PubMed:9890966, ECO:0000303|Ref.5,
FT                   ECO:0000303|Ref.6"
FT                   /id="VSP_000818"
FT   VAR_SEQ         152..154
FT                   /note="AYI -> TVL (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16780893"
FT                   /id="VSP_043910"
FT   VAR_SEQ         155..416
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:16780893"
FT                   /id="VSP_043911"
FT   VARIANT         28
FT                   /note="A -> V (in dbSNP:rs1052571)"
FT                   /evidence="ECO:0000269|PubMed:16780893,
FT                   ECO:0000269|PubMed:8663294, ECO:0000269|PubMed:9890966,
FT                   ECO:0000269|Ref.9"
FT                   /id="VAR_015415"
FT   VARIANT         99
FT                   /note="S -> L (in dbSNP:rs4646008)"
FT                   /evidence="ECO:0000269|Ref.9"
FT                   /id="VAR_015416"
FT   VARIANT         102
FT                   /note="T -> I (in dbSNP:rs2308941)"
FT                   /evidence="ECO:0000269|Ref.9"
FT                   /id="VAR_015417"
FT   VARIANT         106
FT                   /note="L -> V (in dbSNP:rs2308938)"
FT                   /evidence="ECO:0000269|Ref.9"
FT                   /id="VAR_015418"
FT   VARIANT         114
FT                   /note="E -> D (in dbSNP:rs2020897)"
FT                   /evidence="ECO:0000269|Ref.9"
FT                   /id="VAR_015419"
FT   VARIANT         136
FT                   /note="F -> L (in dbSNP:rs1132312)"
FT                   /id="VAR_059198"
FT   VARIANT         173
FT                   /note="R -> H (in dbSNP:rs2308950)"
FT                   /evidence="ECO:0000269|Ref.9"
FT                   /id="VAR_015420"
FT   VARIANT         176
FT                   /note="G -> R (in dbSNP:rs2308949)"
FT                   /id="VAR_016131"
FT   VARIANT         185
FT                   /note="I -> M (in dbSNP:rs9282624)"
FT                   /id="VAR_022053"
FT   VARIANT         192
FT                   /note="R -> C (in dbSNP:rs2308939)"
FT                   /id="VAR_016132"
FT   VARIANT         221
FT                   /note="Q -> R (in dbSNP:rs1052576)"
FT                   /evidence="ECO:0000269|PubMed:8663294, ECO:0000269|Ref.9"
FT                   /id="VAR_015421"
FT   MUTAGEN         153
FT                   /note="Y->F: Inhibits tyrosine phosphorylation. Reduces
FT                   caspase-9 subunit p35 formation in response to genotoxic
FT                   stress. Attenuates ABL1/c-Abl-mediated caspase-3
FT                   activation, DNA fragmentation and UV irradiation-induced
FT                   apoptosis."
FT                   /evidence="ECO:0000269|PubMed:15657060"
FT   MUTAGEN         355
FT                   /note="R->A: Abolished ADP-riboxanation by C.violaceum
FT                   CopC."
FT                   /evidence="ECO:0000269|PubMed:35446120"
FT   CONFLICT        32
FT                   /note="R -> S (in Ref. 2; AAC50776, 3; BAA82697 and 6;
FT                   BAA87905)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        96
FT                   /note="A -> G (in Ref. 1; AAC50640)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        197
FT                   /note="L -> P (in Ref. 2; AAC50776 and 3; BAA82697)"
FT                   /evidence="ECO:0000305"
FT   HELIX           3..11
FT                   /evidence="ECO:0007829|PDB:4RHW"
FT   HELIX           13..19
FT                   /evidence="ECO:0007829|PDB:4RHW"
FT   TURN            23..25
FT                   /evidence="ECO:0007829|PDB:4RHW"
FT   HELIX           26..31
FT                   /evidence="ECO:0007829|PDB:4RHW"
FT   HELIX           37..44
FT                   /evidence="ECO:0007829|PDB:4RHW"
FT   HELIX           51..62
FT                   /evidence="ECO:0007829|PDB:4RHW"
FT   HELIX           69..79
FT                   /evidence="ECO:0007829|PDB:4RHW"
FT   HELIX           83..93
FT                   /evidence="ECO:0007829|PDB:4RHW"
FT   HELIX           143..147
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   TURN            149..151
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          157..159
FT                   /evidence="ECO:0007829|PDB:1JXQ"
FT   STRAND          161..167
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   HELIX           173..175
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   HELIX           183..196
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          199..206
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   HELIX           209..221
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   HELIX           224..226
FT                   /evidence="ECO:0007829|PDB:2AR9"
FT   STRAND          228..239
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          244..246
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          249..251
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          257..259
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   HELIX           260..265
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   TURN            269..271
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   HELIX           273..275
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          280..287
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          317..319
FT                   /evidence="ECO:0007829|PDB:3D9T"
FT   STRAND          340..346
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          351..353
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          354..356
FT                   /evidence="ECO:0007829|PDB:3V3K"
FT   TURN            357..359
FT                   /evidence="ECO:0007829|PDB:1JXQ"
FT   HELIX           362..374
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   TURN            375..377
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   HELIX           380..392
FT                   /evidence="ECO:0007829|PDB:1NW9"
FT   STRAND          395..398
FT                   /evidence="ECO:0007829|PDB:1JXQ"
FT   STRAND          402..406
FT                   /evidence="ECO:0007829|PDB:1JXQ"
FT   STRAND          408..410
FT                   /evidence="ECO:0007829|PDB:1NW9"
SQ   SEQUENCE   416 AA;  46281 MW;  78E0180DF2A3BDD2 CRC64;
     MDEADRRLLR RCRLRLVEEL QVDQLWDALL SRELFRPHMI EDIQRAGSGS RRDQARQLII
     DLETRGSQAL PLFISCLEDT GQDMLASFLR TNRQAAKLSK PTLENLTPVV LRPEIRKPEV
     LRPETPRPVD IGSGGFGDVG ALESLRGNAD LAYILSMEPC GHCLIINNVN FCRESGLRTR
     TGSNIDCEKL RRRFSSLHFM VEVKGDLTAK KMVLALLELA QQDHGALDCC VVVILSHGCQ
     ASHLQFPGAV YGTDGCPVSV EKIVNIFNGT SCPSLGGKPK LFFIQACGGE QKDHGFEVAS
     TSPEDESPGS NPEPDATPFQ EGLRTFDQLD AISSLPTPSD IFVSYSTFPG FVSWRDPKSG
     SWYVETLDDI FEQWAHSEDL QSLLLRVANA VSVKGIYKQM PGCFNFLRKK LFFKTS
//
